OA02.02 Long Term Follow up of Ipilimumab and Targeted Therapy for Metastatic EGFR/ALK Lung Cancer

MLA

Akerley, W., et al. “OA02.02 Long Term Follow up of Ipilimumab and Targeted Therapy for Metastatic EGFR/ALK Lung Cancer.” Journal of Thoracic Oncology, vol. 12, no. 11, Number 11 Supplement 1, Nov. 2017, pp. S1551–52. EBSCOhost, https://doi.org/10.1016/j.jtho.2017.09.010.

APA

Akerley, W., Van Duren, T., Chalmers, A., Luckart, J., Esplin, M., Graves, N., & Cannon, L. (2017). OA02.02 Long Term Follow up of Ipilimumab and Targeted Therapy for Metastatic EGFR/ALK Lung Cancer. Journal of Thoracic Oncology, 12(11, Number 11 Supplement 1), S1551–S1552. https://doi.org/10.1016/j.jtho.2017.09.010

Chicago

Akerley, W., T. Van Duren, A. Chalmers, J. Luckart, M. Esplin, N. Graves, and L. Cannon. 2017. “OA02.02 Long Term Follow up of Ipilimumab and Targeted Therapy for Metastatic EGFR/ALK Lung Cancer.” Journal of Thoracic Oncology 12 (11, Number 11 Supplement 1): S1551–52. doi:10.1016/j.jtho.2017.09.010.